34 reports

  • Global Hepatitis Treatment B Market- By Type
  • North America Hepatitis Treatment B Market Overview

Executive Summary A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Hepatitis B Treatment Market by Type (Therapeutics and Vaccines), By End-User (Male and Female) for...

  • Hepatitis Treatment
  • World
  • Market Size
  • AbbVie Inc.
  • Bristol-Myers Squibb Company

Hepatitis C Therapies Market 2017-2027 ##.

  • Hepatitis Treatment
  • Therapy
  • Forecast
  • Market Shares
  • Market Size

Medicine; ##(##): ##-##.

  • Hepatitis Treatment
  • Market Size
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Janssen Biotech, Inc.

Global Market Study on Hepatitis C Treatment: Online Pharmacies Distribution Channel Segment Expected to Register the Fastest CAGR of ##. ##% During 2016 - 2024 ##.

  • Hepatitis Treatment
  • Therapy
  • World
  • Market Size

These results demonstrate that the triple combination of simeprevir, odalasvir and AL-## has the ability to shorten treatment duration, offer high efficacy and be generally well tolerated in those whose disease is caused by hepatitis C virus (HCV) genotype ## (GT##), one of

  • Hepatitis
  • Hepatitis Treatment
  • Pharmaceutical
  • United States
  • Achillion Pharmaceuticals, Inc.

In June, the company received approval from US FDA for Epclusa, for the treatment of adults with genotype ##-## chronic hepatitis C virus infection.

  • Hepatitis Treatment
  • HIV AIDS
  • United States
  • Company Financials
  • Gilead Sciences, Inc.
  • Gilead Sciences Enters into Licensing Agreement with Hetero Labs

Sovaldi is indicated for the treatment of genotype ##, ##, ## or ## chronic hepatitis C virus (HCV) infection as a component of a combination antiviral treatment regimen.

  • Hepatitis Treatment
  • Therapy
  • India
  • United States
  • Hetero Drugs Limited
  • GILEAD SCIENCES, INC.: COMPANY HISTORY
  • GILEAD SCIENCES, INC.: COMPANY HISTORY

Year 2014 : Contracts/ Agreements; Gilead entered into a new agreement with the Medicines Patent Pool (MPP) to expand access to Gilead' s investigational drug tenofovir alafenamide (TAF) for HIV and hepatitis B, contingent on the medicine' s US regulatory appro

  • Hepatitis Treatment
  • Therapy
  • United States
  • Company
  • Gilead Sciences, Inc.
  • LICENSING AGREEMENTS

The agreement also permit the manufacture of sofosbuvir or ledipasvir in combination with other chronic hepatitis C medicines.

  • Hepatitis Treatment
  • HIV Antiviral
  • Pharmaceutical
  • India
  • Mylan Inc.
  • PRODUCT PROFILE - PREZCOBIX

HIV MEDICINE; ##: ##-##.

  • Hepatitis Treatment
  • East Asia
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • ViiV Healthcare Ltd.

" John' s scientific and business leadership has been notable for the development of Gilead' s portfolio of HIV and viral hepatitis medicines and commitment to worldwide access for patients.

  • Antiviral
  • Hepatitis Treatment
  • United States
  • Corporate Finance
  • Gilead Sciences, Inc.

Associate Professor of Medicine Division of Gastroenterology Department of Medicine, Siriraj Hospital, Mahidol University will be available for interviews in advance via teleconference or onsite.

  • Hepatitis
  • Hepatitis Treatment
  • Infectious Disease
  • World
  • GlaxoSmithKline plc

The American Journal of Medicine; ##(##): ##. e##-##.

  • Hepatitis Treatment
  • United States
  • World
  • Arbutus Biopharma Corporation
  • Gilead Sciences, Inc.
  • Market drivers

IFN has been considered a cornerstone for hepatitis treatment since its launch.

  • Hepatitis Treatment
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.

The American Journal of Medicine; ##(##): ##. e##-##.

  • Hepatitis Treatment
  • Japan
  • World
  • Arbutus Biopharma Corporation
  • Gilead Sciences, Inc.

CLINICAL TRIALS BY PHASE IN G## COUNTRIES HEPATITIS D THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* HEPATITIS D THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* HEPATITIS D THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2017* Country Name Pha

  • Clinical Trial
  • Hepatitis Treatment
  • Pharmaceutical
  • World
  • Product Initiative

Global Hepatitis B Virus (HBV) Market: ##-Year Demand Forecast (2016-2025) ##.

  • Hepatitis Treatment
  • United States
  • World
  • Forecast
  • Gilead Sciences, Inc.

Hepcvir-L is approved as a combination therapy for chronic hepatitis C genotype ## patients.

  • Hepatitis Treatment
  • Pharmaceutical
  • India
  • Company
  • Cipla Ltd
  • NOV 13, 2017: PHARMANIAGA, PHARCO AND DNDI SIGN AGREEMENT TO PROVIDE AFFORDABLE HEPATITIS C TREATMENT IN MALAYSIA
  • OCT 20, 2017: GILEAD ANNOUNCES PRESENTATION ON HARVONI AT THE LIVER MEETING 2017

Gilead Sciences, Inc. announced results from Phase ## and Phase ## studies of its approved medicines for chronic hepatitis C virus (HCV) and hepatitis B virus (HBV) infection, adding to the body of evidence supporting Gilead' s viral hepatitis

  • Hepatitis
  • Hepatitis Treatment
  • Research And Development
  • Therapy
  • Bristol-Myers Squibb Company

Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver Transplantation (LT) GDCT## NCT##, Gastrointestinal Hepatitis B, Liver Cirrhosis Completed Phase IV Observational hepatitis B immune globulin (human) Seoul St.

  • Cytokine
  • Digestive System Disorder
  • Hepatitis Treatment
  • Pharmaceutical
  • World
  • 3. Hepatitis C - Approved Drugs Sales & Forecast
  • The six main reasons for the high price-tags on promising new HCV drugs

This agreement allows Natco to expand access to these chronic hepatitis C medicines in ## developing countries.

  • Hepatitis Treatment
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.

Australia was one of the first countries in the world to subsidize new medicines for all people over the age of ## who have chronic hepatitis C.

  • Antiviral
  • Hepatitis Treatment
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company

Where relevant, CEAF medicines are funded in one of three ways: Group ##A: Drugs which are federally-funded and procured.

  • Hepatitis Treatment
  • Pharmaceutical
  • Brazil
  • Demand
  • GlaxoSmithKline plc

Hepatitis C

4546 5000 3864

Annals of Internal Medicine, ##(##), ##−## < DOI> ##. ##/ M##-##< / DOI>.

  • Hepatitis Treatment
  • European Union
  • Japan
  • North America
  • United States

The American Journal of Medicine; ##(##): ##. e##-##.

  • Hepatitis Treatment
  • World
  • Forecast
  • Arbutus Biopharma Corporation
  • Gilead Sciences, Inc.
  • Clinical Trial profile. 2077 Trial Title

Hepatitis Global Clinical Trials Review, H2, 2015 Summary GlobalData's clinical trial report, “Hepatitis Global Clinical Trials Review, H2, 2015" provides an overview of Hepatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatitis. Report includes an overview of trial...

  • Clinical Trial
  • Drug Discovery And Development
  • Hepatitis Treatment
  • Pharmaceutical
  • World

GLOBAL HEPATITIS C VIRUS MARKET: THE COMPANY COULD BENEFIT FROM THE POTENTIAL GLOBAL HEPATITIS C VIRUS (HCV) MARKET.

  • Antiviral
  • Hepatitis Treatment
  • United States
  • Company
  • Gilead Sciences, Inc.

The drug is indicated for the treatment of chronic hepatitis C virus genotype ## infection.

  • Hepatitis Treatment
  • United States
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • REGIONAL ACCESS TO HEPATITIS C TREATMENTS VARIES IN SPAIN
  • CREATIVE TAXATION MAY BE USED TO MITIGATE BUDGETARY IMPACT OF PAYING FOR NEW HEPATITIS C THERAPIES

The pricing and reimbursement of hepatitis C therapies has been in the spotlight since the launch of Sovaldi in the US in December 2013 at the price of $1,000 per pill. While Sovaldi's and Harvoni’s clinical effectiveness are undisputed, their high prices have prompted widespread criticism from payers, politicians, and patients due to the...

  • Hepatitis Treatment
  • Therapy
  • United States
  • Gilead Sciences, Inc.
  • Humana Inc.
  • 3. Hepatitis C - Approved Drugs Sales & Forecast to

Global sales of Victrelis, an oral medicine for the treatment of chronic hepatitis C, were US$ ## Million in 2013, a decline of ##% compared with 2012 including a ##% unfavorable effect from foreign exchange.

  • Hepatitis Treatment
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Janssen Biotech, Inc.